StemRad, Ltd.

StemRad, Ltd. is a Tel Aviv-Yafo-based company dedicated to developing advanced radiation protection solutions, focusing on technologies that shield critical organ systems from harmful radiation exposure. Founded in 2011, StemRad, Ltd. specializes in radiation protection solutions tailored for medical, military, and space applications.

The firm has engaged in two funding deals, with the latest being a Series C round led by investor Jeff Vinik, raising USD 6. 00 mn in December 2017. The company operates from Tel Aviv-Yafo, Israel, under the leadership of CEO Oren Milstein, while its founder, Daniel L, has a history of entrepreneurship in related fields. StemRad specializes in innovative radiation protection solutions, primarily focusing on selective shielding technologies designed to protect critical organ systems from harmful radiation exposure.

Their flagship products include the AstroRad Radiation Vest and the 360 Gamma Shield, which are engineered to target and shield bone marrow and other vital organs that are highly sensitive to radiation, allowing users to maintain mobility during critical tasks. The company’s technology is particularly relevant for diverse end users, including medical professionals, first responders, military personnel, and astronauts. These products have been deployed in multiple geographical markets, including the United States, Israel, and international space missions, with applications ranging from civilian safety to specialized uses in nuclear facilities and space exploration. StemRad generates revenue through direct sales of its specialized radiation protection products to various sectors, including healthcare, defense, and aerospace.

Transactions typically occur through direct-to-consumer channels as well as B2B partnerships with governmental and institutional clients. The company’s pricing strategy is structured around contracts for bulk purchases, especially for its trademarked products like the 360 Gamma Shield, which has garnered significant interest from organizations such as the National Guard. This approach facilitates large-scale procurement and ensures that clients receive tailored solutions to meet their specific radiation protection needs. StemRad aims to expand its product line with new innovations in radiation protection technology, although specific new products and release dates have not been disclosed.

The company is strategizing to enter new geographic markets, targeting expansion into Europe and Asia by 2025. The recent Series C financing of USD 6. 00 mn will support these initiatives, enabling further research and development as well as marketing efforts for their existing products.